PTK2 and acute myeloid leukemia: Recent studies have indicated that FAK may be a useful therapeutic target for the improved treatment of acute myeloid leukemia cases with poor prognoses (32), and abnormal expression of FAK in patients with MM may be associated with clinical stage and extramedullary infiltration (17).